Biodesix Launches its Liquid Biopsy Mutation Test for Lung Cancer Patients
Biodesix, Inc. has launched its targeted liquid biopsy mutation test for patients with advanced lung cancer.
Biodesix, Inc. has launched its targeted liquid biopsy mutation test for patients with advanced lung cancer.
Bristol-Myers Company today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the investigational compound BMS-663068 when used in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in heavily treatment-experienced adult patients.
On July 10, the U.S. Food and Drug Administration approved Rexulti (brexpiprazole) tablets to treat adults with schizophrenia and as an add-on treatment to an antidepressant medication to treat adults with major depressive disorder (MDD).
Today, Pfizer Inc. announced that US health regulators approved the first drug to treat a rare, progressive lung disease.
The company said that the US Food and Drug Administration (FDA) approved its Rapamune (sirolimus) for the treatment of lymphangioleiomyomatosis (LAM), a rare, progressive disease that affects the lungs, kidneys and the lymphatic system.
The U.S. Food and Drug Administration today authorized use of the first prosthesis marketed in the U.S. for adults who have amputations above the knee and who have rehabilitation problems with, or cannot use, a conventional socket prosthesis.
Dell Inc. has extended its partnership with Translational Genomics Research Institute (TGen) to assist reasearchers and physicians expand the impact and reach of precision medicine efforts for pediatric cancer.
The Patient Access Network Foundation is known for their prolific work in facilitating access to medical treatments for patients with chronic or life-threatening illness. In a survey of people enrolled for assistance with Patient Access Network, most said that PAN assistance helped them in several ways : » Read more